U.S., Jan. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07360288) titled 'Efficacy and Safety of TC011 in Relapsed or Refractory Follicular Lymphoma' on Jan. 14.
Brief Summary: This Phase II, multi-center, single-arm, open-label study evaluates the efficacy and safety of TC011, a CD19-targeted CAR-T cell therapy, in adult patients with relapsed or refractory follicular lymphoma (Grade 1, 2, or 3a).
The primary endpoint is objective response rate (ORR) assessed by independent review using the Lugano 2014 classification.
Study Start Date: March 01
Study Type: INTERVENTIONAL
Condition:
Follicular Lymphoma (FL)
Intervention:
BIOLOGICAL: TC011 single-arm
CD19-targeted chimeric antigen receptor T-cell t...